Vol 15, Issue 6

Montmorency Cherry Juice Consumption does not Improve Muscle Soreness or Inhibit Pro-inflammatory Monocyte Responses Following an Acute Bout of Whole-body Resistance Training.

August 15, 2022 - By 

Authors

Devin Drummer, University of Alabama Birmingham
Kelly Pritchett, Central Washington University
Gina M. Many, Pacific Northwest University
Blaise Dondji, Central Washington University
Kathleen Connor, University of Alabama Birmingham
Jerusalem Tesfaye, Central Washington University
Mark Young, Central Washington University
Robert C. Pritchett, Central Washington University
International Journal of Exercise Science 15(6): 686-701, 2022. 
DOI: 10.70252/AEYR7972

Abstract

Montmorency Cherry Juice (MCJ) may­­­ improve acute exercise recovery by attenuating inflammation and oxidative stress. However, the anti-inflammatory effects of MCJ on monocyte responses following resistance exercise have not been explored. Seven resistance-trained males (age: 22.9 ± 4.1 yrs; height: 1.8 ± 0.1 m; weight: 81.7 ± 13.2 kg) participated in this study. Participants completed a placebo-controlled crossover design, drinking either MCJ or placebo beverages, 7 days prior to completing an acute bout of unilateral resistance exercise. Statistical significance was assessed using a within-subjects repeated measures ANOVA; alpha level p ≤ 0.05. Main effects for time were observed for changes in classical and intermediate monocytes (p ≤ 0.05), but no significant treatment effects were observed for monocyte subtypes p > 0.05. Classical monocytes (CD14+ CD16–) increased and peaked 24 hr post-exercise (placebo 1.14 ± 0.04 and MCJ 1.06 ± 0.06-fold). Intermediate monocytes peaked 48 hr post-exercise increasing 1.82 ± 0.41 and 2.01 ± 0.80-fold. Nonclassical monocytes peaked post-exercise (placebo 1.17 ± 0.31 and MCJ 1.02 ± 0.20-fold). Peak pain visual analog scale (VAS) occurred post-exercise for MCJ (3.63 ± 2.01-fold) and 72 hr post-exercise for placebo (4.26 ± 3.46-fold). IL-6 and pressure pain threshold (PPT) peaked 24 hr post-exercise (IL-6 placebo 3.83 ± 1.01- and MCJ 6.43 ± 3.43-fold) and (PPT placebo 86.37 ± 3.95% and MCJ 82.81 ± 2.90% of pressure needed at pre-exercise). Our data suggests MCJ consumption does not decrease muscle soreness, IL-6, or monocyte subset responses following a high-intensity resistance exercise protocol in resistance-trained males.

Recommended Citation